PrimeRFP SCOUT · Federal Contract Recompete Brief

75A50124C00010Development of a NOVEL pralidoxime chloride — Kaleo, Inc

Kaleo, Inc holds $33.3M across 3 federal awards, concentrated at Department of Health and Human Services (HHS). The prior award was single-bid — competitive dynamics may favor a challenge. Set-aside status: NONE. Recompete timing centers on the Oct 31, 2028 PoP end — agencies typically plan 12–18 months ahead.

Barda - Aspr / Daappo / Barda Dcma

Awarding office

Kaleo, Inc

Recipient

Oct 31, 2028

PoP end

$33.3M

Obligated

541714

NAICS

AN42

PSC

NONE

Set-aside

1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Kaleo, Inc — $90

Contract facts

NONE

Contract number75A50124C00010

AgencyBarda - Aspr / Daappo / Barda Dcma

Awarding officeBarda - Aspr / Daappo / Barda Dcma

IncumbentKaleo, Inc

UEILBM4GLJNDK31

NAICS541714

No full NAICS 541714 intel page yet. Browse NAICS intelligence

PSCAN42

Place of performanceRICHMOND, VA

Related solicitationBAA-23-100-SOL-00004

PoP end (current)Oct 31, 2028

Obligated$33.3M

DEVELOPMENT OF A NOVEL PRALIDOXIME CHLORIDE AUTO-INJECTOR DEVICE is a federal NONE award for Barda - Aspr / Daappo / Barda Dcma held by Kaleo, Inc. Estimated value $33.3M ($33.3M obligated). Current period of performance ends Oct 31, 2028. Last award drew 1 bidder. Place of performance: RICHMOND, VA. Related solicitation BAA-23-100-SOL-00004.

DEVELOPMENT OF A NOVEL PRALIDOXIME CHLORIDE AUTO-INJECTOR DEVICE

Recompete timing

Public

● Expiring in 785 days

Current PoP ends Oct 31, 2028 (785 days remaining). Agencies typically plan 12–18 months ahead — capture window opens around May 1, 2027.

Incumbent footprint

Public record

Kaleo, Inc — $33.3M obligated across 3 awards (firm-wide, all agencies).

Sole agency: Department of Health and Human Services (HHS)

Department of Health and Human Services (HHS)$33.3M · 100% of firm total

Open full company profile →

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 75A50124C00010?

75A50124C00010 (Development of a NOVEL pralidoxime chloride) is a Barda - Aspr / Daappo / Barda Dcma award with an estimated value of $33.3M, currently held by Kaleo, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded 75A50124C00010?

Barda - Aspr / Daappo / Barda Dcma awarded 75A50124C00010 to Kaleo, Inc.

Who is the incumbent on 75A50124C00010?

Kaleo, Inc is the incumbent with $33.3M across 3 related awards in SCOUT’s public footprint. The current period of performance ends Oct 31, 2028.

When does Kaleo, Inc’s 75A50124C00010 come up for recompete?

SCOUT tracks a period-of-performance end of Oct 31, 2028. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Seen enough? Run one full capture cycle on 75A50124C00010 — $90 for 90 days.

This page stays free. Pilot is the live layer: displacement scoring, recompete pipeline, Daily Brief, and SCOUT MCP for 90 days. If you already live in Claude or ChatGPT and only need live search, start MCP Explorer at $29/mo.

Start Pilot — $90

$1/day · one payment · no subscription

Use SCOUT in your AI client — $29/mo

Classify + search inside Claude, ChatGPT, Cursor

Compare plans

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Aug 20, 2026 · refreshed monthlyLatest procurement action May 27, 2026